Retatrutide Dosage Chart & Dosing Schedule Guide

Understanding Retatrutide and Its Purpose

Retatrutide is an investigational weight loss medication developed by Eli Lilly. It is the first in a new class of "triple agonists": while semaglutide (Ozempic, Wegovy) targets the GLP-1 receptor and tirzepatide (Mounjaro, Zepbound) targets GLP-1 and GIP, retatrutide activates GLP-1, GIP and glucagon receptors at the same time. The glucagon component may increase energy expenditure, which is one reason trial weight loss has been larger than with earlier drugs.

Retatrutide is not FDA approved for any use. Everything on this page comes from clinical trial protocols, mainly the Phase 3 TRIUMPH program, and not from a prescribing label. Lilly has said it plans to submit retatrutide to the FDA in the first quarter of 2027.

Because retatrutide affects several pathways in the body, its dosing requires careful management. Starting with the right dose and adjusting it thoughtfully over time can help reduce side effects such as nausea or gastrointestinal discomfort, which are common with this type of medication. Healthcare providers often recommend a gradual titration schedule to allow the body to acclimate to the drug's effects while minimizing adverse reactions. This personalized approach is crucial, as it ensures that patients can reap the full benefits of retatrutide while maintaining their quality of life throughout treatment.

Retatrutide Dosing Schedule: Week-by-Week Breakdown

Starting Low and Going Slow

In the Phase 3 TRIUMPH trials, everyone started retatrutide at 2 mg once weekly by injection under the skin. The dose then went up one step every four weeks until the person reached their assigned target dose of 4 mg, 9 mg or 12 mg. (Earlier Phase 2 trials started some participants at 1 mg.)

Retatrutide Dosage Chart (TRIUMPH Trial Protocol)

Each step lasts four weeks so the digestive system can adjust before the next increase. Side effects are usually strongest in the days after a step up. Because retatrutide is not approved, there is no official consumer dosage chart, and the schedule a prescriber uses after approval may differ from the trials.

What the Trials Found at Each Dose

In TRIUMPH-1, 2,339 adults with obesity or overweight (without diabetes) were assigned to 4 mg, 9 mg, 12 mg or placebo for 80 weeks. Among people who took the drug as intended, average weight loss was 19.0% on 4 mg, 25.9% on 9 mg and 28.3% on 12 mg, compared with 2.2% on placebo. Side effects rose with dose. Nausea affected about 29%, 38% and 42% of people on 4, 9 and 12 mg (15% on placebo), and 4.1%, 6.9% and 11.3% stopped treatment because of side effects (4.9% on placebo).

Each patient's dosing schedule can vary based on their response and any side effects experienced. Regular follow-ups with a healthcare provider are essential to tailor the dose appropriately.

How Retatrutide Dosing Compares to Ozempic and Mounjaro

Retatrutide uses the same once-weekly injection and four-week step-up structure as semaglutide and tirzepatide, but the numbers differ. The table below compares them. Retatrutide figures come from trials; the others come from FDA-approved labels and their pivotal trials.

Milligram doses can't be compared across these drugs. 12 mg of retatrutide is not "stronger" than 15 mg of tirzepatide or weaker than it. There is also no validated way to convert a dose of one drug into another, which is why anyone switching drugs restarts at a low dose.

Factors Influencing Retatrutide Dosage

Individual Health Conditions

Patients with certain health conditions may require special consideration when dosing retatrutide. For example, those with kidney or liver impairment might need dose adjustments or closer monitoring. It's important to discuss your full medical history with your healthcare provider before starting retatrutide.

Response to Treatment

How a patient responds to retatrutide can influence dose changes. If side effects are severe or persistent, the dose may be lowered or the increase delayed. Conversely, if the medication is well tolerated but weight loss or metabolic improvements are insufficient, the dose might be increased within safe limits.

Age and Other Medications

Older adults or those taking other medications may experience different effects from retatrutide. Drug interactions and age-related changes in metabolism can affect how the medication works, so dosing must be personalized accordingly.

Monitoring Your Progress and Side Effects

What to Watch For

The most common side effects in the retatrutide trials were nausea, diarrhea, constipation and vomiting. They were usually mild to moderate and clustered around dose increases. Some trial participants also reported dysesthesia, an unusual skin sensation such as tingling or sensitivity, which was more common at the 9 mg and 12 mg doses. Seek medical advice if side effects are severe, don't improve, or stop you eating and drinking normally.

Regular monitoring of weight, blood sugar levels, and overall health is important. This helps ensure the medication is working as intended and allows for timely dose adjustments.

Using Telehealth for Convenient Care

Accessing expert care for retatrutide dosing and monitoring has never been easier. Doctronic.ai offers 24/7 telehealth visits with licensed doctors across all 50 states. These video visits are affordable, convenient, and allow patients to discuss dosing questions, side effects, and progress from home.

Telehealth can help you understand where retatrutide stands, whether you might qualify for a clinical trial, and which FDA-approved weight loss medications may be options for you today.

Tips for Managing Your Retatrutide Treatment

Stick to the Schedule

Consistency is key when taking retatrutide. Administer your doses on the same day each week to maintain steady medication levels in your body.

Report Side Effects Early

Don't hesitate to contact your healthcare provider or use telehealth services if you experience side effects. Early management can prevent complications and improve your treatment experience.

Combine with Lifestyle Changes

Retatrutide works best when paired with healthy lifestyle habits. Balanced nutrition and regular physical activity support the medication's effects and contribute to long-term success.

Talking to a Doctor About Retatrutide

Retatrutide isn't available by prescription yet. If you're interested in it, a clinician can talk through your health history, explain the trial results in context, and help you weigh approved options such as semaglutide or tirzepatide while retatrutide goes through FDA review. Doctronic offers free AI consultations and video visits with licensed doctors in all 50 states.

Frequently Asked Questions

What is the starting dose of retatrutide?

In the Phase 3 TRIUMPH trials, retatrutide started at 2 mg once weekly by subcutaneous injection. Some Phase 2 participants started at 1 mg. There is no FDA-approved starting dose yet.

How long does it take to reach the maximum retatrutide dose?

In the TRIUMPH trials, it took 16 weeks of four-week steps (2, 4, 6 and 9 mg) to reach 12 mg, so the full dose started in week 17. People assigned to 9 mg reached it in week 13.

What if I miss a dose?

If you miss a scheduled dose, take it as soon as you remember within the same week. If it is close to the next dose, skip the missed one and continue with your regular schedule. Because retatrutide isn't approved, there's no official missed-dose guidance; follow your trial team's or prescriber's instructions.

Are there any foods or medications I should avoid while on retatrutide?

Discuss all medications and supplements with your healthcare provider. There are no specific food restrictions, but maintaining a balanced diet enhances treatment outcomes.

Is retatrutide safe for everyone?

No. Trials excluded people who were pregnant and people with a personal or family history of medullary thyroid carcinoma or MEN2, the same exclusions used for other GLP-1 drugs. Long-term safety is still being studied.

What is the maximum dose of retatrutide?

12 mg once weekly was the highest dose studied in the Phase 3 TRIUMPH trials.

How does retatrutide dosing compare to Ozempic or Mounjaro?

Wegovy tops out at 2.4 mg weekly and Zepbound/Mounjaro at 15 mg. Retatrutide trials went up to 12 mg. The milligram numbers aren't comparable between drugs, and switching from one drug to another means restarting at a low dose.

When will an FDA-approved retatrutide dosage chart be available?

Not until the FDA approves retatrutide. Lilly plans to submit it in the first quarter of 2027, and a typical review takes about 10 to 12 months after the application is accepted, so an official label is unlikely before 2028 unless the review is expedited.

The Bottom Line

Retatrutide is an investigational once-weekly injection, not an FDA-approved drug. In the Phase 3 TRIUMPH trials, dosing started at 2 mg and increased every four weeks to a target of 4, 9 or 12 mg, with 12 mg reached after 16 weeks of escalation. The 12 mg dose produced average weight loss of 28.3% at 80 weeks among people who took it as intended, with GI side effects rising at higher doses. Until an official label exists, treat any retatrutide dosage chart, including this one, as a summary of trial protocols. Talk with a clinician before acting on it. Doctronic's free AI consultations and video visits can help you understand your options. This article is informational and is not a medical diagnosis.